Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-arm, dose escalation and expansion study of low-dose Apatinib combined with Carrelizumab and SOX regimen in first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma

Next Previous
X
Search
Trial Profile

Single-arm, dose escalation and expansion study of low-dose Apatinib combined with Carrelizumab and SOX regimen in first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SPACE Study

    • Most Recent Events

    • 21 Jan 2023 Results (n=33; till data cutoff) of efficacy analysis presented at the 2023 Gastrointestinal Cancers Symposium
    • 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 04 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top